NASDAQ:AKRX - Akorn Stock Price, Forecast & News

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) issued its earnings results on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.06. The firm earned $176.24 million during the quarter, compared to analysts' expectations of $176.15 million. Akorn had a negative net margin of 53.62% and a negative return on equity of 19.95%. The firm's revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.06) earnings per share. View Akorn's Earnings History.

3 Wall Street analysts have issued 12-month target prices for Akorn's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Akorn's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 310.6% from the stock's current price. View Analyst Price Targets for Akorn.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn.

Media headlines about AKRX stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Akorn earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Akorn.

Akorn saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 5,820,000 shares, a decline of 31.6% from the December 15th total of 8,510,000 shares. Based on an average trading volume of 2,180,000 shares, the short-interest ratio is presently 2.7 days. Currently, 6.2% of the company's shares are sold short. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $1.38.

Akorn has a market capitalization of $174.08 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]